Axogen, Inc. AXGN
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
-0.43
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $225.2M | -$15.7M | $167.4M | -$2.9M | $128.8M |
| 2024 | $187.3M | -$10.0M | $142.0M | $1.4M | $103.9M |
| 2023 | $159.0M | -$21.7M | $121.9M | -$19.6M | $95.7M |
| 2022 | $138.6M | -$28.9M | $108.8M | -$36.1M | $101.0M |
| 2021 | $127.4M | -$27.0M | $104.4M | -$41.2M | $112.5M |
| 2020 | $112.3M | -$23.8M | $90.7M | -$31.5M | $123.1M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Levine Alan M | director | 2026-06-19 | Option exercise | 14,150 | — |
| Weiler Kathy Johnson | director | 2026-06-19 | Option exercise | 14,150 | — |
| Wendell Amy McBride | director | 2026-06-19 | Option exercise | 14,150 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.43 (distress)
- Working capital / assets 0.437
- Retained earnings / assets -1.385
- EBIT / assets -0.035
- Equity / liabilities 1.388
Source: SEC EDGAR filings · CIK 0000805928 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.